Want to see TSE:LOVE full AI Analyst Report?
LOVE Stock Chart & Stats
C$1.83
C$0.03(3.90%)
At close: 4:00 PM EST
C$1.83
C$0.03(3.90%)
Day’s Range― - ―
52-Week RangeC$1.45 - C$2.07
Previous CloseN/A
Volume7.64K
Average Volume (3M)45.69K
Market Cap
C$180.77M
Enterprise ValueC$180.34M
Total Cash (Recent Filing)C$21.90M
Total Debt (Recent Filing)C$34.22M
Price to Earnings (P/E)17.5
Beta0.24
Next Earnings
Jul 14, 2026EPS Estimate
0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.11
Shares Outstanding98,782,150
10 Day Avg. Volume37,006
30 Day Avg. Volume45,690
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)1.64
Price to Sales (P/S)1.57
P/FCF Ratio12.31
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
C$3.08Price Target Upside68.49% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)0.12
Revenue Forecast (FY)C$122.76M
Bulls Say, Bears Say
Bulls Say
Strong Revenue Growth And ScaleSustained TTM revenue growth (~53%) reflects expanding market share and improved SKU traction in Canada's regulated adult-use market. Durable top-line expansion helps absorb fixed costs, supports provincial listing retention, and strengthens negotiating leverage with distributors over the next 2–6 months.
Deleveraging And Improved Balance SheetMeaningful deleveraging (D/E ~0.31 vs 0.73 in FY2022) materially improves financial flexibility and reduces refinancing and interest risk. A stronger capital structure supports capacity to invest in cultivation or distribution and cushions the business against regulatory or demand shocks.
Return To Positive Cash GenerationConsistent positive OCF (~27M) and FCF (~15.6M) mark a structural improvement from prior negative cash periods. Reliable cash generation enables reinvestment in yield improvements, working capital, or debt reduction, increasing operational resilience and funding optionality.
Bears Say
Margin CompressionA drop in gross margin from ~44% to ~39% and lower net margins versus FY2025 point to pricing pressure or higher production costs. If structural, sustained margin erosion will weaken cash flow per unit sold and force either cost restructuring or acceptance of lower long-term profitability.
Weak Cash Conversion Relative To Net IncomeFCF at ~53% of net income indicates working-capital absorption or ongoing reinvestment needs that limit cash available for strategic initiatives. Persistent subpar cash conversion reduces the sustainability of reported earnings and constrains flexibility for capex or faster deleveraging.
Earnings Volatility / EPS DeclineMaterial negative EPS growth (~-26%) highlights earnings volatility and sensitivity to margin and volume swings. This undermines predictability of future profitability and complicates multi-quarter planning for investments, pricing, and maintaining returns to shareholders.
Cannara Biotech News
LOVE FAQ
What was Cannara Biotech’s price range in the past 12 months?
Cannara Biotech lowest stock price was C$1.45 and its highest was C$2.07 in the past 12 months.
What is Cannara Biotech’s market cap?
Cannara Biotech’s market cap is C$180.77M.
When is Cannara Biotech’s upcoming earnings report date?
Cannara Biotech’s upcoming earnings report date is Jul 14, 2026 which is in 10 days.
How were Cannara Biotech’s earnings last quarter?
Cannara Biotech released its earnings results on Apr 14, 2026. The company reported C$0.02 earnings per share for the quarter, missing the consensus estimate of C$0.05 by -C$0.03.
Is Cannara Biotech overvalued?
According to Wall Street analysts Cannara Biotech’s price is currently Undervalued.
Does Cannara Biotech pay dividends?
Cannara Biotech does not currently pay dividends.
What is Cannara Biotech’s EPS estimate?
Cannara Biotech’s EPS estimate is 0.05.
How many shares outstanding does Cannara Biotech have?
Cannara Biotech has 98,782,150 shares outstanding.
What happened to Cannara Biotech’s price movement after its last earnings report?
Cannara Biotech reported an EPS of C$0.02 in its last earnings report, missing expectations of C$0.05. Following the earnings report the stock price went down -6.341%.
Which hedge fund is a major shareholder of Cannara Biotech?
Currently, no hedge funds are holding shares in TSE:LOVE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Cannara Biotech
Cannara Biotech Inc., alongside its affiliated entities, specializes in the indoor cultivation, processing, and distribution of cannabis and related products across Canada. The company operates with a dual business model, encompassing both cannabis operations and real estate activities. Its diverse product portfolio is marketed under distinct brand names such as TRIBAL, nugz, and ORCHID CBD. Distribution is managed through both wholesale channels and online retail platforms. Established in 2017, Cannara Biotech Inc. maintains its headquarters in Saint-Laurent, Canada.
LOVE Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a strong financial performance with record-breaking metrics and significant market share growth in key regions and product categories. However, there are challenges in maintaining market share in certain regions and managing cash flow effectively.View all TSE:LOVE earnings summariesLOVE Stock 12 Month Forecast
Average Price Target
C$3.08
▲(68.49% Upside)
Technical Analysis
Jushi Holdings
―
Organigram Global
―
Auxly Cannabis Group
―
Cannabist Company Holdings
―
Grown Rogue International
―
Options Prices
Currently, No data available
---